PPP1R15B inhibitors are a class of chemical agents tailored to selectively bind to and inhibit the function of the protein phosphatase 1 regulatory subunit 15B (PPP1R15B), a protein that plays a regulatory role in various cellular processes. The inhibition of PPP1R15B involves the molecular interaction between the inhibitor molecule and specific sites on the target protein, which can alter the protein's conformation or its ability to interact with other cellular components, thereby modulating its regulatory function. The design and development of PPP1R15B inhibitors are driven by detailed knowledge of the protein's structure and the molecular mechanisms by which it exerts its regulatory effects. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize the three-dimensional structure of PPP1R15B at the atomic level, providing insights into the potential binding pockets where inhibitors could exert their action.
The synthesis of PPP1R15B inhibitors is a highly specialized field that involves the creation of molecules that not only have a high affinity for the target protein but also possess suitable chemical properties to ensure they can adequately penetrate cells and reach the PPP1R15B protein in its native environment. This process often involves the use of combinatorial chemistry, high-throughput screening, and medicinal chemistry techniques to identify and optimize lead compounds that can effectively engage with the protein. The interaction between PPP1R15B inhibitors and their target includes a variety of non-covalent binding forces such as hydrogen bonding, hydrophobic interactions, and van der Waals forces, which contribute to the stability and specificity of the inhibitor-protein complex. Moreover, the development of PPP1R15B inhibitors requires careful consideration of the molecule's selectivity, to minimize interaction with other phosphatases or unrelated proteins that could lead to nonspecific binding and off-target effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
An N-glycosylation inhibitor that induces the UPR by causing protein misfolding in the ER. As PPP1R15B is involved in stress responses, its activity can be modulated when UPR is influenced by tunicamycin. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor that depletes ER calcium, inducing UPR. By influencing UPR, thapsigargin can indirectly modulate PPP1R15B's role in this pathway. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Specifically inhibits eIF2α dephosphorylation, a step regulated by the PPP1R15 family. This inhibition indirectly influences PPP1R15B by altering its target substrate availability. | ||||||
Guanabenz HCl | 23113-43-1 | sc-507500 | 100 mg | $246.00 | ||
Preferentially enhances the dephosphorylation of eIF2α, a substrate for PPP1R15 proteins. By modifying substrate dynamics, guanabenz can indirectly modulate PPP1R15B activity. | ||||||
Guanabenz acetate | 23256-50-0 | sc-203590 sc-203590A sc-203590B sc-203590C sc-203590D | 100 mg 500 mg 1 g 10 g 25 g | $102.00 $468.00 $832.00 $4162.00 $7283.00 | 2 | |
Preferentially enhances the dephosphorylation of eIF2α, a substrate for PPP1R15 proteins. By modifying substrate dynamics, guanabenz can indirectly modulate PPP1R15B activity. | ||||||
ISRIB | 1597403-47-8 | sc-488404 | 10 mg | $300.00 | 1 | |
Reverses the effects of eIF2α phosphorylation without affecting its actual phosphorylation status. This influences UPR dynamics and, consequently, can impact PPP1R15B's function in this pathway. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi apparatus function and induces ER stress. Induction of ER stress influences UPR signaling, potentially affecting PPP1R15B's role. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor that can lead to protein accumulation and ER stress. This can activate the UPR and thus modulate the function of proteins like PPP1R15B involved in the response. | ||||||
4-Phenylbutyric acid | 1821-12-1 | sc-232961 sc-232961A sc-232961B | 25 g 100 g 500 g | $53.00 $136.00 $418.00 | 10 | |
Chemical chaperone that alleviates ER stress, thus influencing the UPR pathway. Its effect on UPR can modulate the activity and role of PPP1R15B in this stress response. | ||||||
Sephin1 | 13098-73-2 | sc-507502 | 5 mg | $578.00 | ||
Selectively inhibits the dephosphorylation of eIF2α substrate, indirectly influencing PPP1R15B by modifying substrate dynamics. | ||||||